Categories Earnings, Health Care

Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot

— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.

— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018

— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018

— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020

— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year

— On track to continue ongoing operations well into 2022, making use of the current cash position

— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA

Get access to timely and accurate in verbatim transcripts that are published within hours of the event

Most Popular

HPE Earnings: Hewlett Packard Q1 2024 profit drops but beats Street view

Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) on Thursday reported lower earnings and revenues for the first quarter of 2024. Earnings, however, exceeded analysts’ forecasts. First-quarter profit, excluding

After entering FY24 on a high note, Costco is all set to report Q2 results

Costco Wholesale Corporation (NASDAQ: COST) stands out in the retail space for its unique business model that enables the warehouse behemoth to grow store traffic and market share constantly. Currently,

Hormel (HRL) expects continued momentum from its foodservice business in FY2024

Shares of Hormel Foods Corporation (NYSE: HRL) soared over 13% on Thursday after the company delivered better-than-expected earnings results for the first quarter of 2024 and reaffirmed its outlook for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top